What is Phoenix Molecular Designs?
Phoenix Molecular Designs, a biotechnology firm based in Vancouver, is dedicated to advancing precision medicine through the development of targeted small molecule drugs. Founded by Dr. Sandra Dunn, the company specializes in RSK inhibitors and companion diagnostics, with its lead candidate, PMD-026, currently in Phase 2 clinical trials for breast cancer. Their focus on tailoring therapies to individual tumor genetics aims to significantly improve treatment outcomes and enhance the quality of life for cancer patients.
How much funding has Phoenix Molecular Designs raised?
Phoenix Molecular Designs has raised a total of $12M across 1 funding round:
Angel/Seed
$12M
Angel/Seed (2019): $12M with participation from Pallasite Ventures and World Changing Ventures
Key Investors in Phoenix Molecular Designs
Pallasite Ventures
Pallasite Ventures is an agile venture capital firm based in Vancouver, Canada, that provides early-stage financing for high-growth companies. They focus on Seed and Series A investments, offering capital between $100k and $1.5m USD to support companies with strong leadership and market vision.
World Changing Ventures
Undisclosed investor participating in the funding round.
What's next for Phoenix Molecular Designs?
The recent major strategic investment positions Phoenix Molecular Designs for accelerated growth and advancement of its clinical pipeline. This capital infusion is expected to fuel the progression of PMD-026 through its clinical trials and potentially support the expansion of its research into other oncology indications. The company's commitment to innovative therapeutic solutions and precision medicine suggests a strategic focus on forging key partnerships and further solidifying its market presence in the competitive biotechnology landscape.
See full Phoenix Molecular Designs company page
